Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Active, not recruiting · Phase 2 · NCT04458610
Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
At a glance
- Research payments reported, 2025
- $285,675
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 60
About the trial
- Sponsor
- M.D. Anderson Cancer Center (with National Cancer Institute (NCI))
- Tested
- Rituximab (biological), Zanubrutinib (drug)
- Dates
- Started 2020-05-26; completion 2027-05-26
- Results posted
- Not yet
This phase II trial studies how well zanubrutinib and rituximab work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma for which the patient has not received treatment in the past (previously untreated). Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. The study is being done to find out if zanubrutinib combined with rituximab can help control previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
From ClinicalTrials.gov, last updated 2026-05-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beigene, Ltd. reported $285,675 in research payments for this study in 2025 (2 payments).
Products named: Brukinsa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $285,675
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.